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Abstract
Background: Due to increasing interest from acne patients concerned about the side effects associated with
conventional therapies, complementary and alternative medicine (CAM) has been suggested as a new therapeutic
modality for acne vulgaris. Herbal medicine is one of these CAM treatments. Cheongsangbangpoong-tang (CBT) is a
common herbal formula used in patients with acne vulgaris in the clinical practice of Korean Medicine (KM).
However, despite the common use of CBT in clinical practice, the current level of evidence is insufficient to support
an inhibitory effect of CBT on inflammatory acne lesions and facial heat. Therefore, this study was designed to
assess the inhibitory effect of CBT on both inflammatory acne lesions and facial heat.
Methods/design: A randomized, double-blind, parallel-group, and placebo-controlled trial will be conducted.
Fifty-six participants with acne vulgaris will be randomized into one of two groups: the CBT or placebo groups.
After randomization, participants will be prescribed either CBT or placebo three times a day at a dose of 5 g after
meals for 8 weeks. The following outcome measurements will be used in the examination of subjects: the mean
percentage change and the count change of the inflammatory and non-inflammatory acne lesions, the temperature of
facial points on digital infrared thermal imaging (DITI), serum cortisol, serum dehydroepiandrosterone-sulfate (DHEA-S),
visual analogue scale (VAS), investigator global assessment (IGA), and severity score on the Korean Acne Grading
System (KAGS) from baseline to the end of the trial.
Discussion: This trial will provide evidence regarding the inhibitory effect of CBT on inflammatory acne lesions and
facial heat. The findings of this trial may have important implications for the more widespread use of CBT for the
treatment of acne vulgaris.
Trial registration: The trial is registered with the Clinical Research Information Service (CRiS), Republic of
Korea: KCT0001468.
Keywords: Acne vulgaris, Inflammatory lesion, Facial heat, Herbal medicine, Cheongsangbangpoong-tang
* Correspondence: ssljh@khu.ac.kr
2Department of Sasang Constitutional Medicine, College of Korean Medicine,
Kyung Hee University, 23 Kyungheedae-roDongdaemun-gu, Seoul 02447,
Republic of Korea
3Korean Medicine Clinical Trial Center, Kyung Hee University Korean Medicine
Hospital, 23 Kyungheedae-roDongdaemun-gu, Seoul 02447, Republic of
Korea
Full list of author information is available at the end of the article
© 2016 Kim et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kim et al. BMC Complementary and Alternative Medicine  (2016) 16:21 
DOI 10.1186/s12906-016-1000-9
Background
Acne is a multifactorial inflammatory skin disease of the
pilosebaceous unit [1]. With respect to pattern identifica-
tion, which is defined as “the process of overall analysis of
clinical data to determine the location, cause and nature
of a patient’s disease” [2], acne is deeply relevant to the
‘Heat’ pattern [3, 4]. Patients diagnosed as suffering from
a ‘Heat’ pattern, such as the ‘Wind-Heat’ or ‘Dampness-
Heat’ patterns, in their dermatologic disease have charac-
teristics similar to the inflammatory state [5].
In Korea, Cheongsangbangpoong-tang (CBT) has been
approved by the Korea Food and Drug Administration
as a prescription for clinical use in patients with acne,
and is most frequently used by Korean Medicine (KM)
clinicians in patients with acne vulgaris. CBT was first
mentioned in ‘Wanbinghuichun’ as a novel herbal
therapeutic formula. It cleans the upper energizer
pathogenic heat, which is considered the major patho-
genic cause of acne in Korean traditional medicine,
and treats the sores and furuncles on the head and
face [6]. However, until now, no well-designed and
randomized clinical trial supporting this classic sub-
stance has been performed.
We hypothesized that CBT inhibits acne inflamma-
tory lesions and facial heat mainly displayed by pa-
tients identified as suffering from a ‘Heat’ pattern. The
purpose of this research is to evaluate the inhibitory
effects of CBT, an herbal formula, on both inflamma-
tory acne lesions and facial heat in patients with acne
vulgaris.
Method/design
Aim of the study
The primary objective of the present trial is to investi-
gate the inhibitory effects of the herbal formula CBT
on both inflammatory acne lesions and facial heat in
patients with acne vulgaris.
The primary null hypothesis is as follows: CBT
treatment is superior to placebo treatment in its in-
hibitory effect on the mean percent change in inflam-
matory acne lesions between baseline and the end of
the trial.
Design
This study is a randomized, placebo-controlled, parallel-
group, double-blind and single-center trial. This trial is reg-
istered with the Clinical Research Information Service
(CRiS), Republic of Korea: KCT0001468. The study will be
sequentially conducted as follows: enrollment after screen-
ing via inclusion and exclusion criteria, randomization, a
treatment period of 8 weeks, and assessment.
In addition, the protocol will be conducted in accord-
ance with the Declaration of Helsinki and the Good
Clinical Practice Guidelines [7]. All investigators are
appropriately qualified to conduct and supervise the
trial. All patients will provide written informed consent
prior to study entry. The flow chart of this study is
shown in Fig. 1.
Ethics
The study protocol and written informed consent were
approved by the Institutional Review Board (IRB) of
the Kyung Hee University Korean Medicine Hospital
(KOMCIRB-150213-HR-006). Each participant will be
provided with information regarding the study proto-
col. Written informed consent will be obtained from
each patient. The privacy of all participants will be
protected. Personal medical records will be reviewed
by investigators, who will promise to keep the content
confidential. Data anonymity will be used in the process of
data management. Finally, the data of all subjects will be
kept in the document storage room of Kyung Hee Korean
Medicine-Clinical Trial Center (K-CTC).
Participants and eligibility
Inclusion criteria
Patients with acne vulgaris aged over 19 years, who
have more than 10 inflammatory acne lesions on
their face (from the jawline margin to the front
margin of hairline), and who agree to use only the
intervention in this study for acne vulgaris treatment
during this trial period are eligible to participate in
this trial.
Exclusion criteria
We will exclude patients with laboratory findings in the
following ranges: aspartate transaminase (AST) ≥ 60 IU/
L, alanine transaminase (ALT) ≥ 60 IU/L, and creatin-
ine > 1.2 mg/dl. Participants will be ineligible if they have
undergone Western medical treatment or traditional
Fig. 1 Flow chart of the study
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medical treatment or taken oral contraceptives/anti-
biotics for acne within 2 weeks prior to recruitment
or are pregnant, lactating, or planning to become
pregnant during the study. Participants will also be
excluded if they are not willing to comply with this
study protocol. During the 8 weeks after enrollment
in this trial, no concomitant acne therapy will be
permitted.
Recruitment
Participants will be recruited via an internet advertise-
ment posted on the website of the Kyung Hee Medical
Center and via posted flyers. A total of fifty-six patients
will be recruited in this trial.
Randomization and allocation concealment
Using a stratified block randomization method, 56 eligible
patients will be randomly allocated to the CBT or placebo
groups in a 1:1 ratio in blocks of 4. Random numbers will
be generated by a computerized random-number gener-
ator using the block-randomization method of a software
program (R 3.2.2) for sequence generation by an in-
dependent statistician. The randomization lists will be
concealed in a lightproof sealed envelope. The sealed
envelopes will be kept by the independent statistician of
the study. Participants, investigators and outcome asses-
sors will be blinded to the treatment allocation throughout
the course of the study.
Blinding and code breaking
Drugs (CBT and placebo) have been coded, providing
masking to the treatment assignment to ensure double
blinding. Patients, clinicians, outcome assessors, and
investigators are unaware of treatment group assign-
ments or block size. If a participant has a serious
adverse event and immediate cessation of trial medica-
tion is required, the blinding code will be broken.
Intervention
CBT and placebo groups
CBT granule is approved by the Korea Food and Drug
Administration as a prescription for use in clinical prac-
tice for patients with acne. The components of CBT are
presented in Table 1. Each of the CBT crude materials
was extracted with 500 mL of hot water for 48-72 hours.
The extracts were filtered, concentrated, lyophilized, and
stored at -60 °C. The yield of CBT dried extract was
approximately 15.8 % (w/w, dry weight 1.5 g). The other
excipients (corn starch and lactose CARB) were added
to this dried CBT extract. CBT granules were purchased
from the Han Kook Sin Yak Pharm. Co., which is
equipped with a Korean good manufacturing practice
(KGMP) facility. A voucher specimen (# KCTC 001502)
was deposited at K-CTC.
Participants assigned to the placebo group will receive a
placebo prescription instead of the herbal formula CBT
throughout the 8-week post-randomization period. The
placebo will not have any clinical or pharmacological ef-
fects. The placebo is almost identical to the test drug in
appearance, smell and taste. This placebo preparation will
be produced and purchased from the Jeonnam Biofood
Technology Center, which is equipped with a Korean good
manufacturing practice (KGMP) facility. The placebo
granules, designed to match the CBT granules, to be used
in this trial are identically sized granules filled with lactose
powder (95.2 %), dextrin (2.94 %), herbal incense (0.7 %)
and coloring (food coloring such as brown food coloring)
(1.16 %), without any markings or active ingredients.
All drugs are concealed in uniform packages with
the same labels in the Jeonnam Biofood Technology
Center and each package contains a 28-day supply.
Patients in the CBT or placebo groups will take each
packaged granule containing either 5 g CBT or 5 g
placebo as a single dose. All drugs will be dissolved
in 200 ml warm water and will be taken orally after
each meal 3 times daily for 8 weeks. During the
study, patients will be visited three times by the in-
vestigators. We will establish the window for visits
as ±3 days. Details of the study procedures are
shown in Table 2.
Outcome measures
Primary outcome
Primary outcome will be presented as the mean percent-
age change of inflammatory lesion counts from baseline
to the end of the trial [8, 9].
Table 1 Components of Cheongsangbangpoong-tang (CBT)
granules (5 g / dose)
Scientific name Amount (g)
Schizonepeta tenuifolia 0.5
Coptis japonica Makino 0.5
Mentha arvensis var. piperascens 0.5
Ponciri Fructus Immaturus 0.5
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Secondary outcomes
Secondary outcomes will evaluate the mean percentage
change of non-inflammatory lesions and the total of both
inflammatory and non-inflammatory lesions, the differ-
ences in temperatures of the DITI points on the face,
Visual Analogue Scale (VAS) [score 0 (no symptoms) to
100 (severe symptoms)], and the Investigator Global
Assessment scale for Facial Acne Vulgaris (IGA; after
evaluation from score 0 (clear) to 4 (severe)) [10] from
baseline to the end of the trial (at 8 weeks) between CBT
treatment and the placebo control groups. Serum cor-
tisol and dehydroepiandrosterone-sulfate (DHEA-S) will
be assessed using clinical laboratory tests at weeks 0
(baseline) and 8 (end of the trial).
VAS and IGA will be checked every session from base-
line (just before randomization) through the 8 weeks
after randomization. A Lumix DMC-LX2 digital camera
(Panasonic, Osaka, Japan) will be used to photograph
the front and both sides of each patients face, so that the
inflammatory and non-inflammatory lesions can be
counted independently at weeks 0 (baseline), 4 and 8
(end of the trial) by a clinical specialist who has been in
clinical practice for more 5 years. We will consider black
and white head comedones to be non-inflammatory
lesions and the inflammatory papules, pustules and cysts
to be inflammatory lesions.
Correlations between the inflammatory lesion count
and the temperatures of the DITI points at baseline,
4 weeks, and 8 weeks, and the frequency of abnormal
liver and kidney function during this trial will also be
secondary outcomes. Additionally, we will analyze the
correlation between the temperatures of the DITI points
and the severity of the Korean Acne Grading System
(KAGS) at baseline and the end of the trial (at 8 weeks).
Finally, we will analyze the success rate of blinding
between the actual treatment and the perceived treat-
ment allocations.
Withdrawal, dropout, discontinuation and compliance
Participants will be allowed to withdraw at any time
during this clinical trial. Participants who wish to with-
draw will be offered the option to cease trial interven-
tion, but continue the visits for outcome measurement.
Participants who withdraw will be followed to investigate
the reason for withdrawal. Participants may be advised
to discontinue this trial if there is a serious intervention-
related adverse event or if the participant is noncompli-
ant with the study procedure. CBT or placebo remaining
after each session will be quantified in order to measure
and enhance medication compliance. Participants whose
compliance with CBT or placebo is ≤ 80 % of the total
will be considered to have dropped out.
Standard operation procedures for quality assurance
We have established detailed standard operating proce-
dures for this clinical trial and have educated all practi-
tioners and set qualification standards to make sure the
patients are treated with high standards and in accordance
Table 2 Detailed study procedures
Items Screening/run-in period Visit 1 (baseline) Visit 2 Visit 4 (endpoint)
Week of the trial -1 0 4 8
Demographic information-taking +
Informed consent form +
General medical history-taking +
Photographing the patient’s face Count
of inflammatory/non-inflammatory lesions
+ + + +
Blood tests (AST, ALT, creatinine, serum cortisol,
serum DHEA-S)
+ +
Urine pregnancy test + + +
Digital infrared thermal imaging + + +
Randomization & allocation +
Distribution of treatment or placebo + +
Visual analogue scale + + +
Investigator Global Assessments + + +
Korean Acne Grading System + + +
Pattern identification for acne +
Monitoring adverse events + +
Compliance check + +
Blinding check +
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with the trial protocol. Practitioners and medical equip-
ment managers attended a 2-day training workshop about
the trial procedures and were educated on methods for
taking a picture of the patient’s face and how to examine
the DITI, serum cortisol, DHEA-S, VAS, KAGS and IGA.
A written protocol and standardized recording doc-
uments will be provided. All practitioners and out-
come assessors will be blinded to group allocations,
and medical equipment managers will not participate
in the interventions.
Adverse events and safety monitoring
All unexpected adverse events related to CBT or the
placebo intervention will be reported to the investigator
by participants and written on the individual case report
form by the investigator. Safety will be assessed by the
reporting of clinical laboratory tests and adverse events.
Clinical laboratory tests, including AST / ALT and creatin-
ine, will be performed at screening and week 8 (the end of
the trial). Each participant will be monitored for adverse
events (pain at acne lesions or other sites, nausea/vomit-
ing, fatigue, allergic reaction, and any adverse events
related to intervention) after each visit.
Statistical methods
Statistical analysis plan
Statistical analyses will be conducted on both intension-
to-treat (ITT) and per-protocol (PP) bases, with a 95 %
confidence interval using SPSS version 12.0 for Win-
dows. Based on the ITT population, the primary out-
come and safety outcome will be tested. Secondary
outcome will be analyzed on both the ITT and PP popu-
lations. The ITT analysis will consider all randomized
participants with at least one measurable outcome value
during the study. Missing values from drop-out partici-
pants will be imputed by the last observation carried
forward (LOCF) method. Data will be displayed as the
mean ± standard deviation (SD) for continuous data or n
(%) for categorical data.
Baseline data and outcome data
An independent T test will be performed for comparison
of the baseline values between the CBT and placebo
groups. The independent T test will be used to examine
the mean percentage change of the inflammatory/non-
inflammatory lesion counts, the differences in the tem-
peratures of the DITI points on the face, sebum level,
serum cortisol, DHEA-S, VAS, and IGA at baseline and
at the end of the trial (at week 8) between the CBT
treatment and placebo control groups. Safety tests (AST,
ALT and creatinine) will be analyzed using the independ-
ent T test at screening and at the end of the trial (at
week 8) between the CBT treatment and placebo control
groups. A repeated measured analysis of covariance
(ANCOVA) test will be used to examine the percentage
change of inflammatory and non-inflammatory lesions,
differences in the temperatures of the DITI points on
the face, VAS, and IGA at weeks 0, 4, and 8 when control-
ling for baseline and other covariates. The correlation
between inflammatory lesion count and the facial skin
superficial temperature points at baseline, 4 weeks, and
8 weeks will be examined using the Pearson correlation
test. Additionally, we will analyze the correlation between
the temperatures of the DITI points and the severity of
the KAGS using the Pearson correlation test. The change
of KAGS from baseline to week 8 will be assessed using a
Chi-square test or Fisher’s exact test. All adverse events
reported during the study will be included in the case
report forms; the incidence of adverse events will be
calculated. The percentage of subjects with adverse events
in each group will be calculated and compared using a
Chi-square test or Fisher’s exact test. The evaluation of
blinding success between the actual treatment and the
perceived treatment allocations will be performed using a
Chi-square test or Fisher’s exact test.
Sample size
Calculation of the sample size for this trial was based on
the effect size of the primary outcome, mean percent
change of inflammatory acne lesion counts from baseline
to week 8, reported in a previously published study [11].
The mean and standard deviation (SD) of the mean percent
change of inflammatory acne lesion counts were -32.4 ± 44
and -15.1 ± 44.9 for the active treatment and control
groups, respectively. To achieve 80 % power (β = 0.20), a
significance level of 0.05 (α) in a two-tailed test, calculated
using Cohen's d effect size values for t-tests (0.39), 28
participants, based on an estimated 20 % dropout rate,
are needed for each group. This results in a required
total of 56 for the trial. The mean and SD of the mean
percent change of inflammatory acne lesion counts
from this pilot study will be used for recalculation of
the sample size for larger trials.
Discussion
CBT is widely used for the treatment of acne in clinical
practice, but the underlying mechanism has not yet been
proven. Moreover, there has been only limited research
on its efficacy for inflammatory acne lesions or facial
heat sensitivity. Thus, this clinical research trial was
designed to provide evidence of the inhibitory effect of
CBT on inflammatory acne lesions or facial heat sensi-
tivity in patients with acne.
Our research was designed to be precise, in that we
will use the placebo to maintain the double blinding of
all assessors and practitioners, and have provided prior
education to all practitioners. Blinding is an important
scientific method in randomized controlled trials (RCT)
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[12]. Most RCT intend to include a double-blind design
to exclude the potential influence of the natural course of
the disease or any expectations of the participants and
investigators [13]. In reality, because of the unique sensory
and macroscopic characteristics, such as the appearance,
taste and smell of herbal preparations, it is extremely diffi-
cult to prepare a placebo that is perceived to be identical
to the real herbal formula while lacking any pharmaco-
logical or toxic activities [12, 13]. Consequently, we will
perform an evaluation of blinding success.
The trial duration of 8 weeks was determined after con-
sidering the following issues: the lasting effectiveness time
of the intervention and its tolerability by and compliance
of the participants. This protocol was developed according
to the guidelines for randomized controlled trials investi-
gating Chinese herbal medicine [14] and follows the nine
CONSORT checklist items for RCTs of herbal medicines
[15]. We considered the main elements for conducting a
high-quality RCT, such as randomization, sequence gener-
ation, allocation concealment, blinding methods, proper
sample size, compliance with the protocol, and adequate
outcome measures [15]. This research will provide im-
portant evidence regarding the more widespread use of
CBT for the treatment of acne vulgaris.
Trial status
Participant recruitment will commence on October 19,
2015. It is anticipated that the trial will be completed in
April 2016.
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